Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics

Journal of Clinical Investigation

Volumn 99, Issue 7, 1997, Pages 1467-1471

  Coller, Barry S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ARGINYLGLYCYLASPARTIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0030999134     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119307     Document Type: Review

References (34)

1. The EPIC Investigators. 1994. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med. 330:956-961.
2. Topol, E.J., R.M. Califf, H.F. Weismann, S.G. Ellis, J.E. Tcheng, S. Worley, R. Ivanhoe, B.S. George, D. Fintel, M. Weston, K. Sigmon, K.M. Anderson, K.L. Lee, and J.T. Willerson, on behalf of the EPIC Investigators. 1994. Randomized trial of coronary intervention with antibody against platelet IIb/ IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 343:881-886.
3. Olshansky, S.J., and A.B. Ault. 1986. The fourth stage of the epidemiologic transition: the age of delayed degenerative diseases. Milbank Mem. Fund Q. 64:355-391.
4. 4th American College of Chest Physicians Consensus Conference on Antithrombotic Therapy. Tucson, Arizona, April 1995 Proceedings. Chest. 108: 225S-522S.
5. Coller, B.S. 1980. Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: defective platelet-fibrinogen interaction in thrombasthenia. Blood. 55:169-178.
6. Savage, B., E. Saldívar, and Z.M. Ruggeri. 1996. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 84:289-297.
7. Ware, A.J., and B.S. Coller. 1995. Platelet morphology, biochemistry and function. In Williams Hematology. E. Beutler, M.A. Lichtman, B.S. Coller, and T.J. Kipps, editors. McGraw-Hill, Inc. New York. 1161-1201.
8. Goldsmith, H.L., and V.T. Turitto. 1986. Rheological aspects of thrombosis and haemostasis: basic principles and applications. ICTH Report. Subcommittee on Rheology of the International Committee on Thrombosis and Haemostasis. Thromb. Haemostasis. 55:415-435.
9. Thiruvikraman, S.V., A. Guha, J. Roboz, M.B. Taubman, Y. Nemerson, and J.T. Fallon. 1996. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab. Invest. 75:451-461.
10. Coller, B.S. 1990. Platelets and thrombolytic therapy. N. Engl. J. Med. 322:33-42.
11. Reverter, J.C., S. Béguin, H. Kessels, R. Kumar, H.C. Hemker, and B.S. Coller, 1996. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J. Clin. Invest. 98:863-874.
12. Diacovo, T.G., S.J. Roth, J.M. Buccola, D.F. Bainton, and T.A. Springer. 1996. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood. 88:146-157.
13. Marcus, A.J., L.B. Safier, M.J. Broekman, N. Islam, J.H. Fliessbach, K.A. Hajjar, W.E. Kaminski, E. Jendraschak, R.L. Silverstein, and C. von Schacky. 1995. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Thromb. Haemostasis. 74:213-217.
14. Coller, B.S., U. Seligsohn, H. Peretz, and P.J. Newman. 1994. Glanzmann thrombasthenia: new insights from an historical perspective. Semin. Hematol. 31:301-311.
15. Coller, B.S. 1995. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation. 92:2373-2380.
16. Cook, N.S., G. Kottirsch, and H. Zerwes. 1994. Platelet glycoprotein IIb/IIIa antagonists. Drugs Future. 19:135-159.
17. Lefkovits, J., E.F. Plow, and E.J. Topol. 1995. Platelet glycoprotein IIb/ IIIa receptors in cardiovascular medicine. N. Engl. J. Med. 332:1553-1559.
18. Zaidi, T., L.V. McIntire, D.H. Farrell, and P. Thiagarajan. 1996. Adhesion of platelets to surface-bound fibrinogen under flow. Blood. 88:2967-2972.
19. Coller, B.S. 1992. Inhibitors of the platelet glycoprotein IIb/IIIa receptor as conjunctive therapy for coronary artery thrombolysis. Coron. Art. Dis. 3: 1016-1029.
20. Jordan, R.E., C.L. Wagner, M. Mascelli, G. Treacy, M.A. Nedelman, J.N. Woody, H.F. Weisman, and B.S. Coller. 1996. Preclinical development of c7E3 Fab; a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. In Adhesion Receptors as Therapeutic Targets. M.A. Horton, editor. CRC Press, Inc., Boca Raton. 281-305.
21. Barrett, J.S., G. Murphy, K. Peerlinck, I. De Lepeleire, R.J. Gould, D. Panebianco, E. Hand, H. Deckmyn, J. Vermylen, and J. Arnout. 1994. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin. Pharmacol. Ther. 56:377-388.
22. Harrington, R.A., N.S. Kleiman, K. Kottke Marchant, A.M. Lincoff, J.E. Tcheng, K.N. Sigmon, D. Joseph, G. Rios, K. Trainor, D. Rose, et al. 1995. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am. J. Cardiol. 76:1222-1227.
23. Aguirre, F.A., D.J. Talley, J.J. Ferguson III, J. Tcheng, N.S. Kleiman, E.A. Montague, J.E. Booth, and A.M. Lincoff. 1996. Efficacy of abciximab, despite patient weight, using lower heparin dosing during percutaneous coronary intervention. Circulation. 94:I-198a. (Abstr.)
24. Ward, S.R., A.M. Lincoff, D.P. Miller, J.E. Booth, E.A. Montague, J. Tcheng, and E.J. Topol. 1996. Clinical outcome is improved at 30 days regardless of pre-treatment clinical and angiographic risk in patients receiving abciximab for angioplasty: results from the EPILOG study. Circulation. 94:I-198a. (Abstr.)
25. Wilentz, J.R., T.A. Sanborn, C.C. Haudenschild, C.R. Valeri, T.J. Ryan, and D.P. Faxon. 1987. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation. 75:636-642.
26. Groves, H.M. R.L. Kinlough-Rathbone, and J.F. Mustard. 1986. Development of nonthrombogenicity of injured rabbit aortas despite inhibition of platelet adherence. Arteriosclerosis. 6:189-195.
27. Coller, B.S., J.L. Kutok, L.E. Scudder, D.K. Galanakis, S.M. West, G.S. Rudomen, and K.T. Springer. 1993. Studies of activated GPIIb/IIIa receptors on the luminal surface of adherent platelets. Paradoxical loss of luminal receptors when platelets adhere to high density fibrinogen. J. Clin. Invest. 92:2796-2806.
28. Moliterno, D.J., R.M. Califf, F.V. Aguirre, K. Anderson, K.N. Sigmon, H.F. Weisman, and E.J. Topol. 1995. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am. J. Cardiol. 75: 559-562.
29. Aguirre, F.V., E.J. Topol, J.J. Ferguson, J.C. Blankenship, L.H. Gardner, E.A. Caracciolo, T.J. Donohue, R.A. Harrington, and J.E. Tcheng, for the IMPACT-II investigators. 1996. Effect of platelet glycoprotein IIb/IIIa antagonism with Integrelin on activated clotting times during coronary interventions: results from the IMPACT-II trial. Circulation. 94:I-197a. (Abstr.)
30. Ammar, T., L.E. Scudder, and B.S. Coller. 1997. In vitro effects of the platelet GPIIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation. 95:614-617.
31. Coller, B.S., J.D. Folts, L.E. Scudder, and S.R. Smith. 1986. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood. 68:783-786.
32. Matsuno, H., J.M. Stassen, J. Vermylen, and H. Deckmyn. 1994. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation. 90:2203-2206.
33. van der Zee, R., J. Passeri, J.J. Barry, D.A. Cheresh, and J.M. Isner. 1996. A neutralizing antibody to the alpha v beta 3 integrin reduces neointimal thickening in a balloon-injured rabbit iliac artery. Circulation. 98:I-257a. (Abstr.)
34. 2, a monoclonal antibody to the platelet GPIIb/IIIa receptor, protects against microangiopathic hemolytic anemia and microvascular thrombotic renal failure in baboons treated with C4b binding protein and a sublethal infusion of Escherichia coli. Blood. In press.